Galvokimig (UCB9741) Disease area studied Abbreviated title Phase Study ID Registry database Study results Publication (if available) Atopic Dermatitis A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis ATD002 Ongoing NCT072776602025-522578-35-00 Atopic Dermatitis A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis Phase 2 UP0089 Completed NCT04643457 LINK Chronic Obstructive Pulmonary Disease A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (SCALA) Phase 2 COPD01 Ongoing NCT07725939
